Metabolic dysfunction-associated steatotic liver disease is now the commonest chronic liver disease, and its overlap with colorectal cancer has been under-managed. An international Delphi panel of 35 experts reached consensus on all 17 statements about this link.

The panel agreed that MASLD is associated with a higher risk of colorectal cancer, that greater metabolic burden raises it further, and that more severe MASLD tracks with worse outcomes in those who develop colorectal cancer. The gut-liver axis and dysbiosis are implicated. On management, the consensus highlighted weight loss through lifestyle change, earlier and risk-adapted colorectal cancer screening, bariatric surgery and GLP-1 receptor agonists as potential risk-reduction strategies.

The practical message is to treat MASLD as a marker of raised colorectal cancer risk and to keep screening and metabolic management on the agenda, rather than viewing the liver disease in isolation. This is consensus built on associations, so it argues for vigilance and shared decisions, not a fixed new screening schedule.

International Delphi consensus of 35 experts on colorectal cancer risk in MASLD.
MASLD is associated with higher colorectal cancer risk, rising with metabolic burden.
More severe MASLD tracks with worse outcomes in those who develop colorectal cancer.
Suggested risk reduction: weight loss, earlier screening, bariatric surgery and GLP-1 agonists.
Treat MASLD as a reason for heightened colorectal cancer vigilance.

Why it matters

It reframes MASLD as more than a liver problem, linking it to colorectal cancer risk that is often overlooked.

Don't overread it

This is expert consensus built on observational associations; it supports vigilance and earlier screening discussions, not a proven causal link or a fixed new screening schedule.